emorubicin hydrochloride (PNU-152243A) administered via intra-hepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: phase II study preceeded by a dose escalatio

• Conditions: Treatment of unresectable hepatocellular carcinoma; MedDRA version: 14.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2005-000731-26-IT
• Lead Sponsor: ERVIANO MEDICAL SCIENCES

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-05
• Last Update Posted: 7 January 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Presence of unresectable, microscopically confirmed HCC, not amenable to any ablation, either newly diagnosed or relapsing after prior surgery, or other prior ablative techniques, or other prior anticancer therapy for HCC, provided that the lesion(s) present at study entry are vascularized through hepatic artery. If biopsy is contraindicated, computerized tomography (CT) or magnetic resonance imaging (MRI) evidence of hepatic tumor and an AFP level of >/=400 ng/mL will be accepted as evidence of HCC. Intermediate risk populations: Tumor staging CLIP 0-1, bilirubin /= 2 cm in at least 1 diameter with conventional CT scan or MRI or >/= 1 cm in at least 1 diameter with spiral CT scan. (For Phase II only) 5. Resolution of all acute toxic effects of any prior surgical procedure or other ablative techniques to NCI CTC Grade /= 18 yrs of age and Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Histologic classification of HCC, fibrolamellar variant. 2. Current enrollment in another clinical trial. 3. Patients with vascular invasion (in particular, with complete obstruction of the portal vein) as documented by imaging techniques (for intermediate risk population only). 4. Patients with extra-hepatic spread. 5. Administration of any prior systemic or intra-arterial anticancer therapy for HCC containing platinum derivatives. 6. Prior liver transplantation. 7. Administration of any prior radiotherapy to treat the tumor lesion(s) present at study entry. 8. Extrahepatic metastatic disease including known brain or leptomeningeal disease (baseline CT or MRI scan of the brain required only in case of clinical suspicion of central nervous system metastases). 9. No longer applicable. 10. Presence of clinically detectable ascites or pleural effusions 11. Recent bleeding (within prior 6 months) from esophageal varices. 12. Symptomatic ulceration of the gastric or duodenal mucosa /= 2 years. 16. Any of the following in the past within the last year: myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event. 17. Any prior history of symptomatic congestive heart failure. 18. Irreversible cardiac arrhythmias requiring permanent medication or uncontrolled arterial hypertension (arterial pressure >/=200/110 mmHg). 19. Active infection other than chronic active hepatitis. Patients with known human immunodeficiency virus (HIV) positivity or acquired-immunodeficiency-syndrome (AIDS)-related illness are not eligible. 20. Pregnancy or breast-feeding. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of chemotherapy. Male patients must be surgically sterile or must agree to use effective contraception during the period of chemotherapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. 21. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. 22. Allergy to the contrast agent.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified